PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 2 | 1 | 56-64
Article title

Efekty leczenia iniekcjami doszklistkowymi ranibizumabu w ramach grupy terapeutycznej B02 pacjentów z wysiękową postacią zwyrodnienia plamki związanego z wiekiem

Content
Title variants
EN
The results of wet AMD treatment by intravitreal injections of ranibizumab within the framework of the therapeutic group B02
Languages of publication
PL
Abstracts
EN
Introduction into medicine of the drugs which inhibit angiogenesis is comparable with introduction of antibiotics in the 20th century. Admission in Poland, in September 2010, the most effective therapy of the wet form of AMD in which intravitreal injections containig monoclonal antibody anti-VEGF (ranibizumab) is used, introduced new standards of the treatment of wAMD. This therapy is refunded by NFZ. The aim of this article is to evaluate the effects of the AMD treatments within the framework of the therapeutic group B02.
PL
Wprowadzenie do medycyny leków hamujących angiogenezę porównywane jest do ery wprowadzenia antybiotyków w XX w. Udostępnienie w Polsce we wrześniu 2010 r. w ramach refundacji NFZ najnowocześniejszej i dotychczas najbardziej skutecznej terapii wysiękowej postaci zwyrodnienia plamki związanego z wiekiem z zastosowaniem iniekcji doszklistkowych przeciwciała monoklonalnego anty-VEGF (ranibizumab) wprowadziło nowe standardy leczenia. W niniejszym artykule podjęliśmy próbę oceny efektów leczenia w postaci wysiękowej AMD w ramach grupy terapeutycznej B02.
Discipline
Publisher
Journal
Year
Volume
2
Issue
1
Pages
56-64
Physical description
References
  • 1. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000; 342(7): 483-492.
  • 2. Van Newkirk MR, Nanjan MB, Wang JJ, et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 2000; 107(8): 1593-1600.
  • 3. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119(6): 1175-1183.
  • 4. Brown DM, Michels M, Kaiser PK, et al.; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
  • 5. Rosenfeld PJ, Brown DM, Heier JS, et al.; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.
  • 6. Holz G, Amoaku W, Donate J, et al. Safety and efficacy of flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophtalmology 2011; 118(4): 663-671.
  • 7. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58.
  • 8. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al.; MONT BLANC Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology 2012; 119(5): 992-1000.
  • 9. Kaiser PK, Boyer DS, Cruess AF, et al.; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology 2012; 119(5): 1001-1010.
  • 10. Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol 2011; 89(3): 208-217.
  • 11. Chakravarthy U, Harding SP, Rogers CA, et al.; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382(9900): 1258-1267.
  • 12. Ho AC, Busbee BG, Regillo CD, et al.; HARBOR Study Group. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014; 1(11): 2181-2192.
  • 13. Veselý P, Synek S. Repeatability and reliability of the visual acuity examination on logMAR ETDRS and Snellen chart. Cesk Slov Oftalmol 2012; 68(2): 71-75.
  • 14. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity 100 measurements. Retina 2010; 30(7): 1046-1050.
  • 15. Carneiro AM, Mendonça LS, Falcão MS, et al. Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting. Clin Ophthalmol 2012; 6: 1149-1157.
  • 16. Kaiser PK. Prospective evaluation of visual acuity assessment: a comparison of snellen versus ETDRS charts in clinical practice (An AOS Thesis). Trans Am Ophthalmol Soc 2009; 107: 311-324.
  • 17. Lim LA, Frost NA, Powell RJ, et al. Comparison of the ETDRS logMAR, compact reduced logMar’ and Snellen charts in routine clinical practice. Eye (Lond) 2010; 24(4): 673-677.
  • 18. Lalwani GA. All about PRONTO: study yielded good results in AMD with treatment guided by OCT. Retina Today 2007; 41-48.
  • 19. Boyer DS, Heier JS, Brown DM, et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009; 116(9): 1731-1739.
  • 20. Canan H, Sızmaz S, Altan-Yaycıoğlu R, et al. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis. Clin Interv Aging 2014; 9: 141-145.
  • 21. Arias L, Roman I, Masuet-Aumatell C, et al. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina 2011; 31(7): 1261-1267.
  • 22. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
  • 23. Holz F, Bandello F, Gilies M, et al.; LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophtalmol 2013; 97(9): 1161-1167.
  • 24. Rauch R, Weingessel B, Maca SM, et al. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration. Retina 2012; 32(7): 1260-1264.
  • 25. Praca zbiorowa. Wytyczne leczenia wysiękowej postaci AMD lekiem Lucentis (ranibizumab). Okulistyka, wyd. specjalne, luty 2012: 7-11.
  • 26. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology 1989; 96: 1416-1419.
  • 27. Lim JH, Wickremasinghe SS, Xie J, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol 2012; 153(4): 678-686.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-9f329da3-31e0-4a81-9fe9-4f3d45cb2e44
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.